Your browser doesn't support javascript.
Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19.
Nagai, Kazumasa; Kitamura, Katsuya; Hirai, Yuji; Nutahara, Daisuke; Nakamura, Hironori; Taira, Junichi; Matsue, Yubu; Abe, Masakazu; Kikuchi, Miho; Itoi, Takao.
  • Nagai K; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Kitamura K; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Hirai Y; Department of Infectious Disease, Tokyo Medical University Hachioji Medical Center, Japan.
  • Nutahara D; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Nakamura H; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Taira J; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Matsue Y; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Abe M; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Kikuchi M; Department of Gastroenterology and Hepatology, Tokyo Medical University Hachioji Medical Center, Japan.
  • Itoi T; Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan.
Intern Med ; 60(2): 231-234, 2021 Jan 15.
Article in English | MEDLINE | ID: covidwho-1067518
ABSTRACT
Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pancreatic Neoplasms / SARS-CoV-2 / COVID-19 / Antineoplastic Agents Type of study: Case report / Diagnostic study Topics: Long Covid Limits: Aged / Humans / Male Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Internalmedicine.6294-20

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pancreatic Neoplasms / SARS-CoV-2 / COVID-19 / Antineoplastic Agents Type of study: Case report / Diagnostic study Topics: Long Covid Limits: Aged / Humans / Male Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Internalmedicine.6294-20